LUPIN
LUPIN · NSE
₹2,014
+0.76% (+₹15.2)
Prev. close
₹1,998.8
Volume
6,30,830
Delivery %
59.7%
As of
20 Nov 2026
Price history
Axis Securities Analysis · Axis Securities · 02 Jul 2025, 12:30 IST
“Bullish on Lupin Ltd, with a target price of ₹2,500, indicating a 29% upside. This optimism is based on robust new product launches, an expanding portfolio of complex generics, and a strong pipeline, with new US market introductions like Darunavir and Spiriva capturing significant market shares.”
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Bullish on LUPIN, recommending to buy above ₹2116 with a stop loss at ₹2089 and an intraday target of ₹2160. This is bas…” | Raja VenkatramanNeoTrader | Lupin Ltd | MISS | ||||
| “Bullish on Lupin, recommending a buy above ₹2045 with a target of ₹2175 within two months and a stop loss at ₹1980. The …” | Raja VenkatramanNeoTrader | Lupin Ltd | HIT | ||||
| “Recommends buying Lupin with a target price of ₹2,404. The call implies a bullish outlook on the stock.” | Deven ChokseyIndependent | Lupin Ltd | HIT | ||||
| “Citi maintains a 'Buy' rating on Lupin with a target price of ₹2,260. The brokerage believes Lupin's $250 million invest…” | Citi AnalysisCitigroup Inc. | Lupin Ltd | HIT | ||||
| “Recommends buying Lupin at ₹2045, targeting ₹2100, with a stop loss at ₹2020 for intraday trading.” | Vaishali ParekhPrabhudas Lilladher | Lupin Ltd | MISS | ||||
| “Bullish on Lupin for the next 2-3 weeks, targeting ₹2,150 and ₹2,210. The stock broke out from a descending trendline an…” | Vishnu Kant UpadhyayMaster Capital Services | Lupin Ltd | MISS | ||||
| “Recommends buying Lupin Ltd (LUPIN) at ₹1990, with a stop loss at ₹1960 for a target price of ₹2050. The stock exhibits …” | Ganesh DongreAnand Rathi | Lupin Ltd | MISS | ||||
| “Bullish on Lupin, recommending a buy at ₹970 with a target of ₹2,050 and a stop loss of ₹1,924. A bullish harami pattern…” | Rupak DeLKP Securities | Lupin Ltd | MISS | ||||
| “Bullish on Lupin, recommending a buy at ₹1970 with a target of ₹2050 and a stop loss at ₹1924. The stock formed a bullis…” | Rupak DeLKP Securities | Lupin Ltd | MISS | ||||
| “Upgraded Lupin to 'Buy' with a target price of ₹2,375, citing continued growth momentum in North America and India, alon…” | Choice Institutional Equities AnalysisChoice Institutional Equities | Lupin Ltd | HIT | ||||
| “Bullish on Lupin, recommending a buy at ₹1952 with a target of ₹2050 and a stop loss at ₹1920.” | Vaishali ParekhPrabhudas Lilladher | Lupin Ltd | MISS | ||||
| “Bullish on Lupin Ltd, with a target price of ₹2,500, indicating a 29% upside. This optimism is based on robust new produ…” | Axis Securities AnalysisAxis Securities | Lupin Ltd | MISS | ||||
“Bullish on Lupin Ltd, with a target price of ₹2,500, indicating a 29% upside. This optimism is based on robust new product launches, an expanding portfolio of complex generics, and a strong pipeline, with new US market introductions like Darunavir and Spiriva capturing significant market shares.” Target ₹2,500Track opinion → How it resolved: R4 TARGET_CALL: entered ₹1954.8 on 2025-07-03 (next trading session's close); neither target nor stop reached by window end 2026-07-02. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention. (02 Jul 2026) | |||||||
| “Maintains a 'buy' rating on Lupin, targeting ₹2,500, expecting strong performance in the pharmaceutical sector, driven b…” | Axis Securities AnalysisAxis Securities | Lupin Ltd | MISS | ||||
| “Has a Buy rating on Lupin stock with a target price of ₹2,466. This positive outlook is based on the stock's strong tech…” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Lupin Ltd | MISS | ||||
| “Bullish on Lupin, targeting ₹2,284 in the near to medium term, with strong support at ₹1,985. The stock has broken out f…” | Vishnu Kant UpadhyayMaster Capital Services | Lupin Ltd | MISS | ||||
| “Axis Securities has an 'overweight' call on Lupin with a target price of Rs 2,500. The company's growth is expected to b…” | Axis Securities AnalysisAxis Securities | Lupin Ltd | MISS | ||||
| “Bearish on Lupin, recommending a short position for the upcoming week with a target price of ₹1,840 and a stop loss at ₹…” | Rajesh PalviyaAxis Securities | Lupin Ltd | MISS | ||||
| “Recommends buying Lupin with a target price of ₹2,472. The call is based on the company's strong fundamentals and growth…” | Deven Choksey Research AnalysisDeven Choksey Research | Lupin Ltd | MISS | ||||
| “Bullish on Lupin Ltd, recommending a buy at ₹2,185 with a target of ₹2,220-2,235 and a stop loss at ₹2,173. The stock is…” | Ankush BajajIndependent | Lupin Ltd | MISS | ||||
| “Recommends buying Lupin Ltd at ₹2,185 with a target of ₹2,220-2,235 and a stop loss at ₹2,173. The stock shows bullish s…” | Ankush BajajIndependent | Lupin Ltd | MISS | ||||
| “Axis Securities maintains an 'overweight' call on Lupin, setting a target price of ₹2,600 against the current market pri…” | Axis Securities AnalysisAxis Securities | Lupin Ltd | MISS | ||||
| “Bullish on Lupin, indicating a potential near-term target of ₹2,500. Bansal highlights several bullish patterns on month…” | Madu BansalThe Finberg | Lupin Ltd | MISS | ||||
| “Bullish on Lupin, advising traders to ride the trend and buy on dips towards ₹2,300. He sets a stop loss below ₹2,200 fo…” | Ruchit JainMotilal Oswal Financial Services | Lupin Limited | MISS | ||||
| “Recommends accumulating Lupin with a target price of ₹2,472. The call implies a bullish outlook on the stock.” | Deven Choksey Research AnalysisDeven Choksey Research | Lupin Ltd | PENDING | ||||
| “Prabhudas Lilladher recommends buying Lupin with a target price of ₹2,420. The call implies a bullish outlook on the sto…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Lupin Ltd | PENDING | ||||
| “Recommends selling Lupin Ltd. at ₹2,153, targeting ₹2,080, with a stop loss at ₹2,190 for today.” | Vaishali ParekhPrabhudas Lilladher | Lupin Ltd. | MISS | ||||
| “Bullish on Lupin, recommending a buy at ₹2,204 with a target price of ₹2,350 and a stop loss at ₹2,135. The stock has bo…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Lupin Ltd | MISS | ||||
| “Recommends buying Lupin at ₹2,156, targeting ₹2,240, with a stop loss at ₹2,100. This is a short-term buy call for today…” | Vaishali ParekhPrabhudas Lilladher | Lupin Ltd | PENDING | ||||
| “Recommends buying Lupin with a target price of ₹2,500. The brokerage sees significant scope for margin improvement from …” | Axis Securities AnalysisAxis Securities | Lupin Ltd | PENDING | ||||
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “PL Asset Management, led by Siddharth Vora, is bullish on the value segment within the pharma sector, preferring names t…” | Siddharth VoraPL Asset Management | Lupin | — | |
| “Recommends adding Lupin, projecting a 15.4% upside. This is included in their large-cap conviction picks for December 20…” | InCred Equities AnalysisInCred Equities | Lupin | — | |
| “Nuvama recommends buying Lupin and has raised its target price post Q2FY26 results, highlighting robust profitability, m…” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Lupin Ltd | — | |
| “Lupin is likely to move from the large-cap list to the mid-cap category in AMFI's January 2026 review, effective from Fe…” | Abhilash PagariaNuvama | Lupin Ltd | — | |
| “Lupin is identified as a top pick by Axis Securities, suggesting a bullish stance. The firm expects an earnings recovery…” | Axis Securities AnalysisAxis Securities | Lupin Ltd | — | |
| “Nomura is bullish on Lupin, maintaining a buy rating after the company’s €190 million acquisition of VISUfarma. This acq…” | Nomura AnalysisNomura Global Markets Research | Lupin Ltd | — | |
| “Bullish on Lupin, which is showing early reversal signs and is poised to break a falling trend line above ₹2,000. Moment…” | ETMarkets AnalysisETMarkets.com | Lupin Ltd | — | |
| “Maintained a 'Neutral' stance on Lupin, revising its target price downward to ₹2,000. While acknowledging the earnings s…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Lupin Ltd | — | |
| “Nuvama has reiterated a positive stance on Lupin, reaffirming confidence in the company’s prospects and projecting over …” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Lupin Ltd | — | |
| “Choice Broking remains bullish on Lupin, despite legal setbacks in the U.S. market that have delayed generic drug launch…” | Choice Institutional Equities AnalysisChoice Institutional Equities | Lupin Ltd | — | |
| “Recommends buying Lupin Ltd. in the range of ₹2,140–2,200, targeting a profit goal of ₹2,650 with a stop loss at ₹1,970.…” | Marketsmith India AnalysisMarketsmith India | Lupin Ltd | — | |
| “Bullish on Lupin in the short term. The stock closed with strong volumes above its September 2024 swing high of ₹2,312, …” | ETMarkets AnalysisETMarkets.com | Lupin Ltd | — |
About Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Ms. Vinita D. Gupta
Headquarters
Mumbai
Employees
26,021
Website
lupin.comExchange
View on NSE ↗Key stats
Market cap
₹90,534.27 Cr
P/E ratio (TTM)
16.5
Dividend yield
0.89%
EPS (TTM)
₹120.29
Beta (1Y · daily vs NIFTY 50)
0.52
Beta (5Y · monthly vs NIFTY 50)
0.82
Shares float
24.21 Cr
EPS · quarter ended Jun 2026
₹30.89
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹15,162.96 Cr | ₹16,405.48 Cr | ₹16,641.66 Cr | ₹20,010.82 Cr | ₹22,707.90 Cr | ₹27,958.03 Cr | |
EBITDA | ₹2,703.17 Cr | ₹428.91 Cr | ₹1,871.48 Cr | ₹3,898.12 Cr | ₹5,479.13 Cr | ₹8,682.54 Cr |
| ₹1,216.53 Cr | ₹-1,528.04 Cr | ₹430.08 Cr | ₹1,914.48 Cr | ₹3,281.62 Cr | ₹5,332.84 Cr | |
Diluted EPS | ₹26.97 | ₹-33.65 | ₹9.41 | ₹41.87 | ₹71.69 | ₹116.44 |
Net income for Mar 2022 could not be checked against the company's own annual report: this page shows ₹-1,528.04 Cr while the annual report gives ₹-1,509.36 Cr (1.2% apart). That disagreement leaves the whole cross-check inconclusive, so Net income for Mar 2020 (the annual report alone gives ₹-269.78 Cr) is left blank here too, rather than shown from only one of the two sources.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹23,430.00 Cr | ₹21,651.00 Cr | ₹22,800.00 Cr | ₹23,751.00 Cr | ₹28,978.00 Cr | ₹38,146.00 Cr | |
| — | ₹4,158.38 Cr | ₹4,541.52 Cr | ₹2,921.77 Cr | ₹5,447.77 Cr | ₹6,616.18 Cr | |
Stockholders' equity | ₹13,803.00 Cr | ₹12,153.00 Cr | ₹12,465.00 Cr | ₹14,290.00 Cr | ₹17,203.00 Cr | ₹22,448.00 Cr |
Total debt, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,239.38 Cr | ₹1,082.38 Cr | ₹1,897.24 Cr | ₹3,648.36 Cr | ₹2,999.94 Cr | ₹7,334.50 Cr | |
Investing cash flow | ₹-657.20 Cr | ₹577.16 Cr | ₹-1,286.77 Cr | ₹-1,712.20 Cr | ₹-4,171.89 Cr | ₹-3,864.59 Cr |
| ₹-1,885.00 Cr | ₹-1,572.00 Cr | ₹-337.00 Cr | ₹-2,184.00 Cr | ₹1,732.00 Cr | ₹-846.00 Cr | |
Capital expenditure | ₹-678.00 Cr | ₹-905.00 Cr | ₹-1,500.00 Cr | ₹-929.00 Cr | ₹-1,682.00 Cr | ₹-2,055.00 Cr |
End cash position | ₹920.63 Cr | ₹991.37 Cr | ₹1,264.59 Cr | ₹983.76 Cr | ₹1,543.69 Cr | ₹4,167.73 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25–Sep 25(2Q) | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 46.83% | 46.81% | 46.78% | 47.10% | 47.11% | 47.10% | 47.08% | 47.07% | 47.06% | 47.04% | 47.01% | 46.98% | 46.96% | 46.95% | 46.92% | 46.90% | 46.89% | 46.86% | 46.85% |
| Public | 53.15% | 53.18% | 53.22% | 52.90% | 52.89% | 52.90% | 52.92% | 52.93% | 52.94% | 52.96% | 52.99% | 53.02% | 53.04% | 53.05% | 53.08% | 53.10% | 53.11% | 53.14% | 53.15% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Lupin Limited | ₹92,244.53 Cr | ₹2,008.6 | 16.7 | 4.11 | 23.8% | 0.29 | +23.9% | +0.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.